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ABSTRACT
Somatic mutations in GNAQ gene were described as being the main oncogenic ac-
tivation in uveal melanomas, whereas mutations in BRAF gene have been described
as a key genetic alteration that contributes to skin melanoma development. We have
previously reported diVerential activation of the MAPK and AKT/mTOR signalling
pathways in uveal and skin melanomas harbouring, respectively, GNAQ and BRAF
mutations. The aim of this work was to compare the functional eVect of GNAQ and
BRAF mutations in mTOR and MAPK pathway activation, cell proliferation and
apoptosis. In this work, we performed transient transfection of HEK293 cells with
BRAFWT, BRAFV600E, GNAQWT, GNAQQ209P and GNAQQ209L vectors. We treated
melanoma cell lines displaying diVerent BRAF and GNAQ mutational status with
the mTOR inhibitor RAD001 and with the MEK1/2 inhibitor U0126 and evaluated
the eVects in the growth of the cell lines and in mTOR and MAPK pathway eVectors
expression. At variance with the signiﬁcant increase in the level of pmTOR Ser2448
and pS6 Ser235/236 proteins observed in cells transfected with BRAF vectors, no
signiﬁcant alteration in mTOR pathway eVectors was observed in cells transfected
withthethreeGNAQexpressingvectors.Also,GNAQoverexpressionenhancesStat3
activation, which might mediate GNAQ oncogenic eVects. None of the vectors led
to signiﬁcant diVerences in proliferation or apoptosis in the transfected cell lines.
Cell lines harbouring a BRAF mutation were more sensitive to RAD001 treatment.
U0126 leads to the reduction of MAPK and mTOR pathways activation in all cell
lines tested. Our results indicate that GNAQ and BRAF activation drive distinct in-
tracellularsignallingpathwaysthatmaybeusefulfortherapeuticdecisionsinhuman
melanomas.
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INTRODUCTION
Melanoma arises from the malignant transformation of the melanocytes (review in
Tolleson,2005).Theskinisthemostcommonsiteformelanomadevelopment,followedby
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clinicalbehaviours(Didolkaretal.,1980).
Ocular melanoma is the most common primary eye tumour in adults, and accounts
for 5% of all melanomas. Most arise in the uvea with >90% occurring in the choroid
and few arising in the ciliary body and iris, and <5% in the conjunctiva (Chang, Karnell
& Menck, 1998). Skin melanoma represents <5% of all skin cancer but is responsible for
the majority of skin cancer-related deaths (www.cancer.org). After metastasis, treatment
options available for ocular and skin melanomas show limited eYcacy (Damato, 2004;
Gray-Schopfer,Wellbrock&Marais,2007;Tarhini&Agarwala,2006).
Melanomagenesis is thought to occur by the accumulation of several genetic and
molecular alterations (Miller & Mihm, 2006; Wolchok & Saenger, 2007), some of which
leadtotheactivationoftheMAPKandAKT/mTORsignalling(Dahl&Guldberg,2007).
Somatic mutations in BRAF gene have been described as key genetic alterations in skin
melanoma development (Smalley & Herlyn, 2004), whereas GNAQ gene was described as
an oncogene in uveal melanomas (Van Raamsdonk et al., 2009). Both alterations are likely
toresultinMAPKpathwayactivation.
In a previous work we reported BRAF mutations in 30% of skin melanomas and
GNAQ gene mutations in 36% of uveal melanomas (Populo et al., 2011a; Populo et al.,
2011b). No signiﬁcant association was found between BRAF or GNAQ mutations and
the expression of phosphorylated ERK1/2 in tumours, as previous reported by others
for BRAF mutations (Houben et al., 2008). An association between BRAF mutation and
elevated mTOR pathway activation was observed in skin melanomas, whereas in a series
of uveal melanomas no association was found between mTOR pathway activation and
GNAQ mutation (Populo et al., 2011a; Populo et al., 2011b). Our group also found in
papillary thyroid carcinoma (that also presents frequent mutation in BRAF gene) an
increased activation of mTOR pathway in BRAF mutated PTC, and in vitro transfection
of BRAFV600E discloseda positiveassociation betweenBRAF (over)expressionand mTOR
pathwayactivation(Faustinoetal.,2012).InactivationofLKB1bySer428phosphorylation
might mediate the association between BRAF expression and mTOR pathway regulation
(Faustinoetal.,2012).
Our aim was to compare in vitro the eVect of GNAQ and BRAF mutations in the
activation of MAPK and mTOR pathways and in the sensitivity to the inhibition of those
pathways.
MATERIAL AND METHODS
Cell lines and culture conditions
The BLM, G361 and Mewo skin melanoma cell lines were kindly provided by Dr. Marc
Mareel, from the Department of Radiotherapy and Nuclear Medicine, Ghent University
Hospital,Belgium.TheA375skinmelanomacelllinewaskindlyprovidedbyDr.Madalena
Pinto, from CEQUIMED, Faculty of Pharmacy, University of Porto, Portugal. 92.1 (De
Waard-Siebinga et al., 1995), OMM1 (Luyten et al., 1996), OMM2.3 (Chen et al., 1997)
and Mel285 (Ksander et al., 1991) uveal melanoma cell lines were kindly provided by Dr.
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 2/16Martine Jager, from the Laboratory of Ophthalmology, Leiden University, Netherlands.
The HEK293 cell line was kindly provided by Dr. Bart Eggen, from the Department
of Neuroscience, University of Groningen, Netherlands. HEK293 cells, derived from
human embryonic kidney cells, were used as a model system to verify the eVect of the
overexpression/activation of BRAF and GNAQ genes in the expression of MAPK and
mTORpathwayseVectors.Allthecelllinesweretestedformycoplasma.
The BLM, Mewo and HEK293 cell lines were maintained in DMEM medium
(Gibco/BRL – Invitrogen), the G361 cell line was maintained in McCoy’s medium
(Gibco/BRL – Invitrogen), and the 92.1, OMM1, OMM2.3 and Mel285 cell lines were
maintained in RPMI medium (Gibco/BRL – Invitrogen). All media were supplemented
with 10% of fetal bovine serum, 100 U/mL Penicillin and 100 ug/mL Streptomycin. Cell
linesweremaintainedinahumidiﬁedatmosphere(5%CO2)at37C.
Expression vectors and cell transfection
The GNAQWT vector was purchased from UMR cDNA Resource Center. The mutant
forms of GNAQ gene (GNAQQ209P and GNAQQ209L) were generated by site-directed
mutagenesis. All plasmids were re-sequenced to conﬁrm that the desired mutations were
introduced without changes to the vector backbone. The coding sequences of GNAQWT,
GNAQQ209P andGNAQQ209L wereclonedintotheexpressionplasmidpcDNA3.1.
Transient transfection of HEK293 cells was performed by the calcium phosphate
co-precipitation method (Clark et al., 1995), 24 h after cells were seeded (1105=well)
in 6-well plates. Cells were transfected with 5 ug of plasmid DNA, which included
500 ng of the expression plasmid (pcDNA3.1-GNAQWT, pcDNA3.1-GNAQQ209P or
pcDNA3.1-GNAQQ209L) or pcDNA3.1- empty vector, 500 ng of pEGFP-C1 (Clontech,
Mountain View, USA) to monitor transfection eYciency, and 4 ug of “carrier DNA”-
pUC18.ConﬁrmationofGNAQincreaseexpressionaswellasofpERK1=2(asareadoutof
GNAQ activity) was done by Western-blotting. BRAF wild-type and mutant vectors were
obtainedasdescribedinFaustinoetal.,2012.
Treatment of melanoma cell lines with RAD001 and U0126
RAD001 (Everolimus, Novartis Pharma AG, Basel, Switzerland) was dissolved in DMSO
andaddedtotheculturemedium.20nMand50nMofRAD001wereusedfor24and48h
treatment. Melanoma cells incubated with culture medium supplemented with DMSO
servedasthecontrol.U0126(Sigma-Aldrich,St.Louis,MO,USA)wasdissolvedinDMSO
andaddedtotheculturemedium.Asrecommendedbythemanufacturer,20MofU0126
wereusedfor24hoftreatment.
Western blot analysis and antibodies
Cells were lysed for 15 min at 4C using RIPA buVer (1% NP-40 in 150 mM NaCl, 50 mM
Tris (pH 7.5), 2 mM EDTA) containing phosphatase and protease inhibitors. Proteins
were quantiﬁed using a modiﬁed Bradford assay (Biorad). Protein samples (50 g) were
separated in 6% or 12% SDS/PAGE gels, depending on the molecule to be analysed,
and electroblotted to Hybond ECL membrane (Amersham Biosciences). We used the
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phospho-S6 Ser235/236, phospho-4E-BP1 Thr37/46, phospho-ERK1/2 Thr202/Tyr204,
raptor(allfromCellSignalingTechnology),rictor(Abnova),andBRAFandGNAQ(Santa
Cruz Biotechnology). Secondary antibodies were conjugated with peroxidase (Santa Cruz
Biotechnology) and visualized by the ECL detection solution. Membranes were re-stained
withagoatpolyclonalanti-actin(SantaCruzBiotechnology)antibodyforloadingprotein
control. All experiments and quantiﬁcations (using Bio-Rad Quantity One 1-D Analysis
software(4.6.6version))wereperformedintriplicate.
BrdU assay
Forty-eight hours after transfection, the cells seeded on coverslips were labelled
by incubation in 10 M of bromodeoxyuridine (BrdU) for 1 h and ﬁxed with 4%
paraformaldehyde. Nuclear incorporation was detected using an anti-BrdU antibody
(Dako).Theproportionofpositivenuclei(BrdUindex)wasdeterminedcountingatleast
500cells.
TUNEL assay
Forty-eight hours after transfection, cytospin preparations of both ﬂoating and attached
cells were collected. Cells were ﬁxed with 4% paraformaldehyde at room temperature,
washed in PBS and permeabilised with 0.1% Triton X-100 in 0.1% sodium citrate
on ice. TUNEL analysis was performed using the “In situ cell death detection kit,
ﬂuorescein” from Roche, following the manufacturer’s instructions. The proportion
ofTUNEL-positivenucleiwasdeterminedfromcountingatleast500cells.
Sulforhodamine B (SRB) assay
Cells were seeded as triplicates in 96-well plates at a density of 6102 for skin melanoma
cell lines and 8  102 for ocular melanoma cell lines in 200 l medium. After 24 h, the
medium was replaced by a medium containing 20 nM of RAD001. Cells were incubated
for 24 and 48 h, ﬁxed in 50 l of cold 50% Trichloroacetic acid, washed with distilled
water, and air dried. 150 l of a SRB solution at 0.1% in 1% acetic acid was then added.
The plates were incubated for 30 min at RT, washed with 1% acetic acid and air dried.
Finally,150lof10mMTris-basewasadded,plateswereshakenandmeasuredat560nm,
using a Synergy Mx microplate reader (BioTek Instruments, Inc., Winooski, VT). The
intensity of absorbance indicates the number of viable cells in the wells (Skehan et al.,
1990). The absorbance of the wells containing culture medium with DMSO and tumour
cells was used as control, whereas culture medium with DMSO alone was used as blank
calibration. Results were expressed as a percentage of the growth relative to the control.
Eachexperimentalconditionwasstudiedwithtriplicatesandrepeatedinduplicate.
DNA extraction and mutation analysis
DNA extraction was done using the Invisorb spin tissue mini kit (Invitek, Berlin).
Fragments encompassing BRAF exon 15, NRAS exon 2 and GNAQ exon 5 were ampliﬁed
by polymerase chain reaction (PCR). Genomic DNA (25–100 ng) was ampliﬁed by PCR
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57 for NRAS and 45 s at 72C for 35 cycles. All PCR products were puriﬁed and directly
sequenced on an ABI Prism 3130 xl Automatic sequencer (Perkin-Elmer, Foster City, CA)
usingtheABIPrismDyeTerminatorCyclesequencingkit(Perkin-Elmer).
Statistical analysis
Statistical analysis was performed using STAT VIEW-J 5.0 (SAS Institute, Inc., Cary, NC).
The data was analysed by the two-tailed unpaired Student’s t-test. A p value <0.05 was
consideredstatisticallysigniﬁcant.
RESULTS
Expression of MAPK and mTOR pathways effectors in transfected
cell lines with GNAQ vectors
TheeYciencyoftransfectionofHEK293cellswithGNAQwt,GNAQQ209P andGNAQQ209L
vectors was as high as 60% in all experiments, assessed by ﬂuorescence microscope, and
also observed by the levels of GNAQ expression and ERK1/2 activation, which was higher
withthemutatedvectorsthanwithGNAQwt vector(Fig.1A).Nosigniﬁcantalterationsof
the mTOR pathway eVectors were observed in HEK293 cells transfected with the three
GNAQ expressing vectors when compared to cells transfected with the empty vector
(Fig.1).
A signiﬁcant increase in the level of pmTOR Ser2448 (p < 0:01 for BRAFwt and
BRAFV600E) and pS6 Ser235/236 (p D 0:01 for BRAFwt and p < 0:01 for BRAFV600E)
proteins was observed when comparing cells transfected with BRAFwt and BRAFV600E
vectorstocellstransfectedwiththeemptyvector.
Comparing HEK293 cells transfected with GNAQ and BRAF vectors, a signiﬁcantly
higher expression of pERK1/2 (p D 0:02 for wt vectors and p < 0:01 for mutated vectors)
and pmTOR (p D 0:01 for wt vectors and p < 0:01 for mutated vectors) was found in the
cells transfected with BRAF vectors (Fig. 2). Cells transfected with BRAFV600E disclosed
higher levels of raptor than cells transfected with GNAQQ209P and GNAQQ209L mutant
vectors.p D 0:03/.AhigherpS6expressionwasfoundincellstransfectedwithBRAFV600E
than in cells transfected with GNAQQ209L vector .p D 0:05/. Although not signiﬁcant, we
also found a tendency for higher pmTOR, raptor and rictor expression in cells transfected
withBRAFV600E thanincellstransfectedwithGNAQQ209L vector.
Proliferation and apoptosis in cell lines transfected with BRAF and
GNAQ vectors
No signiﬁcant alterations were found either in proliferation (BrdU assay) or in apoptosis
(TUNEL assay) when comparing HEK293 cells expressing BRAF and GNAQ vectors with
cellstransfectedwiththeemptyvectors(Fig.S1).
Melanoma cell growth inhibition after treatment with RAD001
The genetic alterations in the mutational hot spot regions of BRAF, GNAQ and NRAS
genesinthe8celllineswereveriﬁed(Table1).
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 5/16Figure 1 (A) Representative Western blot analysis of GNAQ, pERK1/2 and mTOR pathway eVectors ex-
pression in HEK293 cells, transfected with GNAQWT, GNAQQ209P and GNAQQ209L expressing vectors
compared to cells transfected with an empty vector, in at least three sets of experiments; (B) graphic
representation of the mean fold change of activated protein expression observed. Error bars are standard
error.  refers to a signiﬁcant .p < 0:05/ diVerence when comparing cells transfected with GNAQWT,
GNAQQ209P and GNAQQ209L with those with the empty vector.
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 6/16Figure 2 Graphic representation of the mean fold change of protein expression, observed in HEK293
cells, transfected with BRAFwt and BRAFV600E expressing vectors compared to cells transfected with
GNAQWT, GNAQQ209P and GNAQQ209L expressing vectors, in at least three sets of experiments. Error
bars are standard error.  refers to a signiﬁcant .p < 0:05/ diVerence when comparing cells transfected
with each BRAF vectors with all GNAQ vectors.
The eVects of the mTOR pathway inhibitor RAD001 on melanoma cell growth in
monolayer culture was determined by SRB assay (Skehan et al., 1990). Treatment of
melanoma cells with 20 nM and 50 nM of RAD001 yielded variable growth inhibition
in all the cell lines at 24 h and 48 h (Fig. 3A and Fig. S2). Cell lines harbouring BRAF
mutation revealed to be more sensitive to RAD001 than the other cell lines tested, with
growthinhibitionratesof40%and44%at24hand47%and50%at48h,with20nMand
50 nM of RAD001, respectively, which are signiﬁcantly higher than cell lines harbouring
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 7/16Table1 SummaryofBRAF,NRAS,andGNAQmutationalstatusinmelanomacelllines.
Location Cellline Tissue BRAF NRAS GNAQ
Skin melanoma cell lines A375 Skin V600E wt wt
G361 Skin V600E wt wt
BLM Lung metastasis wt wt wt
Mewo Skin wt wt wt
Uveal melanoma cell lines 92.1 Choroid wt wt Q209L
OMM2.3 Liver metastasis wt wt Q209L
Mel 285 Choroid wt wt wt
OMM1 Subcutaneous metastasis wt wt wt
Notes.
wt D wild type.
GNAQmutationsandcelllineswildtypeforbothgenesat24h.p < 0:01/andalsoat48h
oftreatment.p  0:01/.
Expression of mTOR pathway effectors in melanoma cell lines
treated with RAD001
The eYcacy of RAD001 in inhibiting the mTOR pathway was evaluated by Western blot
analysis for PTEN, phosphorylated AKT at Ser473, mTOR at Ser2448, S6 at Ser235/236
and 4E-BP1 at Thr37/46AKTSer473. The results obtained at 24 h of treatment with
20 nM are presented in Fig. 3B. RAD001 eVectively inhibits phosphorylation of S6 and
partially inhibits phosphorylation of mTOR and 4EBP1 in all the evaluated cell lines.
Phosphorylation of AKT was enhanced after treatment with RAD001 and no alteration
was found in PTEN expression. Similar results were observed after 48 h of treatment with
20nMandwith50nMRAD001inthetwotimepoints(datanotshown).
Expression of MAPK and mTOR pathways effectors in melanoma
cell lines treated with U0126
The eYcacy of U0126 in inhibiting the MAPK pathway was evaluated by the levels of
phosphorylated ERK1/2 at Thr202/Tyr204 and the eYcacy in inhibiting the mTOR
pathway was evaluated by analysis of PTEN, phosphorylated AKT at Ser473, mTOR
at Ser2448, S6 at Ser235/236 and 4E-BP1 at Thr37/46. The results obtained at 24 h of
treatment are presented in Fig. 4. U0126 eVectively inhibits phosphorylation of ERK1/2
and also inhibits phosphorylation of mTOR, S6 and 4EBP1 in the evaluated cell lines.
Phosphorylation of AKT was generally enhanced after treatment with U0126 and PTEN
expressionwasnotaltered.
DISCUSSION
Constitutive MAPK activation seems to be a common event in both skin and uveal
melanomas,althoughitoccursthroughdiVerentmechanisms:inskinmelanoma,through
BRAF and NRAS activating mutations (Reifenberger et al., 2004), and in uveal melanoma
MAPK activation can occur through GNAQ activating mutations (Populo et al., 2011b;
Van Raamsdonketal.,2009).
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 8/16Figure 3 (A) Percentage of growth inhibition of melanoma cell lines treated with 20 nM and 50 nM of
RAD001 for 24 and 48 h compared to non-treated cells in six sets of experiments. Error bars are standard
error.  D p < 0:05 (BRAF mutated cell lines versus all other cell lines); (B) representative Western blot
analysis of PTEN, pAKT, pmTOR, pS6 and p4EBP1 expression observed in the melanoma cell lines after
20 nM RAD001 treatment for 24 h compared to non-treated cells; (C) graphic representation of the
mean fold change of activated protein expression observed. Error bars are standard error;  refers to a
signiﬁcant .p < 0:05/ diVerence when comparing cells treated with 20 nM of RAD001 for 24 h compared
to non-treated cells.
In a previous report we described MAPK and AKT/mTOR pathway activations in a
series of skin melanomas, where an association between BRAF mutation and high mTOR
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 9/16Figure 4 (A) Representative Western blot analysis of pERK1/2, PTEN, pAKT, pmTOR, pS6 and p4EBP1
expression observed in the melanoma cell lines after U0126 treatment compared to non-treated cells;
(B) graphic representation of the mean fold change of activated protein expression observed. Error bars
are standard error.  refers to a signiﬁcant (p<0:05) diVerence when comparing cells treated with 20 M
of U0126 for 24 h compared to non-treated cells.
pathway activation was observed (Populo et al., 2011a). In thyroid carcinomas we also
disclosed an association between BRAF mutation and mTOR pathway overactivation
(Faustino et al., 2012). We have observed that BRAF over-expression lead to a signif-
icant increase in the expression level of pmTOR Ser2448 and pS6 Ser235/236 in vitro
(Faustinoetal.,2012).
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melanomas(Populoetal.,2010),butinthosecancersthisactivationdidnotrelatewiththe
presence of GNAQ mutation (Populo et al., 2011b). Taken together, our previous reports
suggest that BRAF activation, but not GNAQ activation, can enhance the activity of the
mTORpathway.
In the present work, GNAQ wild-type and mutant vectors lead to ERK1/2 activation,
in accordance with the results reported by Raamsdonk et al., after transfection of
hTERT/CDK4R24C/p53DD melanocytes with GNAQQ209L vector (Van Raamsdonk et al.,
2009).However,neitherGNAQwild-typenormutatedforms,leadtoanincreaseinmTOR
pathwayactivation,whichisinlinewiththelackofassociationbetweenGNAQmutational
status and mTOR pathway activation that we have reported in human uveal melanoma
samples (Populo et al., 2011b) and also with the lack of alteration in AKT phosphorylation
afterlossofmutantGNAQ,alreadyreportedbyothersinuvealmelanomacelllines(Khalili
et al., 2012). At variance, we observed that, besides ERK1/2 activation, wild-type and
mutant BRAF lead to a signiﬁcant increase in the expression level of pmTOR Ser2448 and
pS6 Ser235/236 in vitro. The activation of mTOR pathway by BRAF is consistent with our
previousstudiesonhumantumours(Populoetal.,2011a).
We performed transient transfection with activated BRAF and GNAQ vectors and
we did not ﬁnd signiﬁcant alterations in proliferation and apoptosis in the cell lines.
Overexpression of BRAFV600E was previously reported to inhibit cell proliferation and
induce senescence in long term experiments (Gray-Schopfer et al., 2006; Michaloglou et
al., 2005), whereas GNAQ overexpression has no eVect in cell growth (Van Raamsdonk
et al., 2009). Further experiments (incorporating transformation of melanocytes and/or
melanoma cell lines) will be necessary in order to verify if a sustained MAPK pathway
activation, with or without concomitant mTOR pathway activation, may be suYcient to
substantially modify proliferation and apoptosis in long term experiments. Alternatively,
other pathways can also be involved in the proliferative burst in these tumours. Recently,
Garcia-Marcos and co-authors reported that activating mutations in GNA01 gene, which
also encodes a G-protein q-subunit, enhances Stat3 activation (Garcia-Marcos, Ghosh &
Farquhar, 2011). Concordantly, GNAQ wild-type and mutated forms also seem to drive
higher expression of pStat3 Tyr705 (Fig. S3), which might mediate GNAQ oncogenic
eVects.
WefoundhighersensitivitytoRAD001treatmentinthecutaneousmelanomacelllines
harbouring a BRAFV600E mutation, in line with the higher expression of pmTOR and pS6
in cells transfected with BRAFV600E. Although all the cell lines displayed a signiﬁcant
reduction of S6 phosphorylation, which is considered a marker of mTOR inhibition
(O’Reilly & McSheehy, 2010), cell lines harbouring a BRAFV600E mutation (A375 and
G361) displayed signiﬁcant higher growth rate inhibition after RAD001 treatment than
the other melanoma cell lines harbouring GNAQQ209L (92.1 and OMM2.3), or BRAFwt
and GNAQwt (BLM, Mewo, OMM1 and Mel285) cell lines. Similar results were reported
by Ho et al. (2012) that observed higher sensitivity to mTOR and MEK inhibition in
uveal melanoma cell lines harbouring BRAF mutations. In our work, we used cutaneous
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 11/16melanoma cell lines where BRAF mutations are the most common alteration and BRAF is
consideredanoncogene(Smalley&Herlyn,2004).Thesedatamightsupportourprevious
suggestion that skin melanoma with BRAF mutation can be more sensitive to mTOR
inhibitiontherapy(Populoetal.,2011a).
Not surprisingly, we veriﬁed that the inhibition of the mTOR pathway, by RAD001,
and the MAPK pathway, by U0126, lead to AKT upregulation. This eVect was previously
reported and is supposed to occur through the abolishment of a S6K1/IRS-1 negative
feedbackandtheinductionofupstreamreceptortyrosinekinasesignalling(O’Reillyetal.,
2006).
In the present study, uveal melanoma cell lines disclosed a signiﬁcant reduction
of S6 phosphorylation and growth inhibition after RAD001 treatment, although at
a signiﬁcantly lower level than the cell lines which harbour a BRAFV600E mutation.
Therefore, we cannot deﬁnitively rule out the clinical potential of mTOR inhibition for
the treatment of human uveal melanomas. Of note, Khalili et al., proposed that PI3K
inhibition enhance the eVects of MEK inhibition and the combination may be an eVective
therapy in uveal melanoma, particularly in a GNAQ mutant background (Khalili et al.,
2012).
We observed that the abolishment of MAPK activity by U0126 treatment leads to
mTOR pathway inhibition. A synergistic reduction of melanoma cell proliferation and
induction of cell death with combined mTOR and MAPK pathway inhibition was already
reported(Gopaletal.,2010;Lasithiotakisetal.,2008;Molhoek,Brautigan&SlingluV,2005),
suggesting that this combined inhibitory therapy may beneﬁt patients with BRAF mutant
melanomas.
It’s worth mentioning that no molecular markers are used in most of the clinical
trials with mTOR inhibitors. Loss of PTEN and activation of AKT were suggested to be
associated with increased tumour cell sensitivity to the mTOR inhibitors (Kurmasheva,
Huang&Houghton,2006),althoughonlythelossofPTENexpressionwasused,inclinical
trials, as a marker to evaluate glioblastoma sensitivity to rapamycin treatment (Cloughesy
et al., 2008). Our results further support that BRAF, already used as a putative predictive
marker of the eVectiveness of MAPK pathway inhibition therapy (www.clinicaltrials.
gov), might also be useful, in skin melanomas, as a predictive marker of mTOR pathway
inhibitiontherapyaloneorincombinationwithMAPKinhibitors.
CONCLUSIONS
To the best of our knowledge, this is the ﬁrst study comparing the cellular eVects of two
major oncogenic events, BRAF and GNAQ mutations, in melanomagenesis using both
cutaneousanduvealmodels.OurresultssuggestthatactivatedBRAFandGNAQgenesdo
notcauseequivalentcellulareVectsandthatonlyBRAFactivationseemstoleadtoahigher
activation of the mTOR pathway. Therefore, the activation of both genes seems to evolve
through diVerent pathways, reinforcing the concept that diverse pathogenic mechanisms
drive the development of skin and uveal melanomas. Thus, strategies for melanoma
therapyshouldconsiderthemutationalstatus,andBRAFmutantmelanomasmaybemore
P´ opulo et al. (2013), PeerJ, DOI 10.7717/peerj.104 12/16sensitivetomTORinhibitiontherapyaloneorincombinationwithMAPKinhibitors,such
as vemurafenib, the BRAFV600E inhibitor already approved for the treatment of advanced
melanoma(www.fda.gov).
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